To analyze the phenotype, genotype, and clinical outcomes of patients with triple-negative primary myelofibrosis (PMF) compared to JAK2-mutated PMF, highlighting the clinical significance of these differences.
Key Findings:
Triple-negative PMF patients had a median age of 65 years and presented with significant anemia (47% severe) and leukocytosis (33% >11 × 10^9/L).
Unfavorable karyotype was found in 19% of triple-negative patients, with 29% harboring high molecular risk mutations, indicating a need for careful monitoring.
Overall survival (OS) was significantly influenced by age, hemoglobin levels, leukocyte count, PB blasts, and karyotype in triple-negative PMF, with specific survival rates to be included.
Interpretation:
Triple-negative PMF presents with distinct clinical features and outcomes compared to JAK2-mutated PMF, with specific risk factors impacting survival, suggesting a need for tailored management strategies.
Limitations:
Retrospective design may introduce bias, potentially affecting the reliability of the findings.
Limited sample size of triple-negative PMF patients may restrict the generalizability of the results.
Conclusion:
Triple-negative PMF patients exhibit unique clinical characteristics and survival outcomes, highlighting the need for tailored management strategies based on identified risk factors.
by Yassin A. Bashir, Ahmed A. Abdelrheem, Maymona Abdelmagid, Kaaren K. Reichard, Rong He, Cinthya J. Zepeda Mendoza, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
